Loading...
A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
BACKGROUND: Late antibody-mediated rejection (ABMR) is a leading cause of transplant failure. Blocking IL-6 has been proposed as a promising therapeutic strategy. METHODS: We performed a phase 2 randomized pilot trial to evaluate the safety (primary endpoint) and efficacy (secondary endpoint analysi...
Na minha lista:
| Udgivet i: | J Am Soc Nephrol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Nephrology
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7920172/ https://ncbi.nlm.nih.gov/pubmed/33443079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2020071106 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|